FGFR4 and non-small cell lung carcinoma: Studies indicate that in NSCLC, the G2041A mutation in FGFR4 can activate the MAPK, PI3K, and JAK-STAT signaling pathways, promoting tumor proliferation, survival, and immune evasion (Ramos-Ramírez et al., 2025).